Hematopoietic Cell Transplantation clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18-70
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Our lead scientists for Hematopoietic Cell Transplantation research studies include Stefan Octavian Ciurea.